Title: *Tests for Sub-Acute Systemic Toxicity of Finished Products* *Report Form*

Customer Code: **M0230030201018/01**
Form Code: F02-P78

Identification

Applicant	Rasa Salamat Arvand		
Address	National Institute of Genetic Engineering and Biotechnology, Pajoohesh Blvd.		
Product Name	Revaheal Sept		
Batch Number	02032331		
Date of Receipt	1403.02.01	**Test Duration**	35 Days
Date of Test	1403.05.19	**Number of Received items**	1 Sample
Date of Report	1403.06.23	**Number of Tested animals**	40 Repeats

Animal Management

Species	Mouse	**Body Weight Range**	25-30 g
Strain/Type	NMRI	**Number of Treated Animals (polar & non-polar extract)**	20
Sex	Male and Female (5 per sex)	**Number of Control Animals (polar & non-polar solvent)**	20

Dosage condition & Route of Administration

Examination type	Acute☐ Subacute ☒ Subchronic ☐ Chronic ☐
Administration site	Gavage☐ Subcutaneous ☐ Intramuscular☐ Intraperitoneal(non-polar)☒ Intravenous(polar) ☒
Dosage volumes (ml/kg)	(Intraperitoneal & Intravenous) 50
Rate of injection	1 ml/min
Study Design	Single Dose Administration

Animal Husbendary

Food	Standard pellet provided from the authorized supplier, and unlimited supply of drinking water
Housing	Healthy animals were acclimatized to the laboratory conditions before the treatment, and then they were housed in spatial cages identified by a card indicating the requiered data
Humidity	at least 30% and preferably not exceed 70%
Lighting	12 hours light, 12 hours dark
Temperature	22 ± 3^0C

Sample preparation

Extraction Time (hours)	72±2 h
Extraction Temperature (℃)	37±1 ℃
Extraction solvent	solution sodium chloride 0.9% (polar) & corn oil (non-polar)
Solvent type	Polar & Non-polar
Extraction method	Dynamic incubation
pH of the test sample	>2 & <11.5 (It was within the acceptable range.)
Negative control	sodium chloride 0.9% & corn oil
Carrier arrival	Hansen connector

021 91 30 9890 0992 60 62 450
Nikopharmed@gmail.com Nikopharmed.com

Description of product

Material composition: This Wound antiseptic solution provides effective disifection while promoting tissue regeneration and accelerating the healing process. It contains silver, Known for its strong antibacterial properties, and chitosan, which enhances wound healing and tissue repair.

Procedure (Sample preparation)

- **Sample preparation was done based on the ISO 10993-12 standard method.**

Extraction vehicles:
Polar: sodium chloride 0.9%
Non-polar: Corn oil

Extraction: The extraction procedure was performed at extraction ratios of 0.2 g/ml.
For the extraction of the internal fiber of the product, and taking into account the absorbent nature of the test material, the water absorption capacity of the sample was first determined. Based on the calculated absorption, the extraction medium was applied at a ratio of 0.2 g/ml.
Extraction temperature and time: 37 ± 1 °C for 72±2 hours

- **Extraction method:** Dynamic incubation in an incubator
- **Extraction container:** Chemically inert, sterile, and tightly sealed
- **Post-extraction handling:** Extracts were collected aseptically and used directly for acute toxicity testing according to ISO 10993-1

Test Results

Polar Extract											
Description	**Acceptable limit**	**Animals No. & Groups**									
		Treatments					**Controls**				
A) Body Weight Changes											
Male		**1**	**2**	**3**	**4**	**5**	**1**	**2**	**3**	**4**	**5**
Beginning of Test (g)	25-30 (g)	25.5	27.2	26.1	25.4	28.2	29.3	26.3	28.7	27.4	25.2
Day 7 (g)		26.1	28.1	25.8	24.5	28.5	30.4	26.7	27.5	28.3	26.1
Day 14 (g)		26.5	26.5	26.5	25.2	29.1	29.4	27.9	26.6	29.4	27.9
Day 21 (g)		27.2	27.5	27.3	26.3	29.6	28.2	27.4	27.3	30.6	28.3
End of Test (Day 28 (g))		28.5	28.4	26.3	27.8	28.9	28.4	27.4	28.8	31.9	28.4
Mean	±20%	27.08					28.15				
± SD		1.32					1.47				
Female		**6**	**7**	**8**	**9**	**10**	**6**	**7**	**8**	**9**	**10**
Beginning of Test (g)	25-30 (g)	26.5	25.3	27.3	29.2	29.4	30.0	26.3	26.4	29.9	29.1
Day 7 (g)		25	27.5	26.7	27.3	27	26.3	28.1	27.3	26.3	27.2
Day 14 (g)		24.8	28.6	26.1	28.5	28.4	27.4	30.4	26.4	28.4	28.3
Day 21 (g)		27.2	29.7	28	29.6	29	28.3	29	27.9	29.2	29.4
End of Test (Day 28 (g))		26.4	27.8	27.4	27.8	30.6	26.5	27.9	28.7	25	32.5

021 91 30 9890 0992 60 62 450
Nikopharmed@gmail.com Nikopharmed.com

Mean	±20%	27.64	28.09
± SD		1.47	1.63

7th Day

B) Clinical Observations

Male		1	2	3	4	5	1	2	3	4	5
Respiratory	N*	N	N	N	N	N	N	N	N	N	N
Motor activities	N*	N	N	N	N	N	N	N	N	N	N
Ocular signs	N*	N	N	N	N	N	N	N	N	N	N
Cardiovascular signs	N*	N	N	N	N	N	N	N	N	N	N
Analgesia	N*	N	N	N	N	N	N	N	N	N	N
Gastrointestinal (Diarrhea, etc.)	N*	N	N	N	N	N	N	N	N	N	N
Convulsion	N*	N	N	N	N	N	N	N	N	N	N
Reflexes	N*	N	N	N	N	N	N	N	N	N	N
Salivation	N*	N	N	N	N	N	N	N	N	N	N
Piloerection	N*	N	N	N	N	N	N	N	N	N	N
Muscle tone	N*	N	N	N	N	N	N	N	N	N	N
Skin	N*	N	N	N	N	N	N	N	N	N	N
Death	-	-	-	-	-	-	-	-	-	-	-
Female		6	7	8	9	10	6	7	8	9	10
Respiratory	N*	N	N	N	N	N	N	N	N	N	N
Motor activities	N*	N	N	N	N	N	N	N	N	N	N
Ocular signs	N*	N	N	N	N	N	N	N	N	N	N
Cardiovascular signs	N*	N	N	N	N	N	N	N	N	N	N
Analgesia	N*	N	N	N	N	N	N	N	N	N	N
Gastrointestinal (Diarrhea, etc.)	N*	N	N	N	N	N	N	N	N	N	N
Convulsion	N*	N	N	N	N	N	N	N	N	N	N
Reflexes	N*	N	N	N	N	N	N	N	N	N	N
Salivation	N*	N	N	N	N	N	N	N	N	N	N
Piloerection	N*	N	N	N	N	N	N	N	N	N	N
Muscle tone	N*	N	N	N	N	N	N	N	N	N	N
Skin	N*	N	N	N	N	N	N	N	N	N	N
Death	-	-	-	-	-	-	-	-	-	-	-

N: No signs of Clinical Observations, **N.M**: Not Measured

14th Day

B) Clinical Observations

Male		1	2	3	4	5	1	2	3	4	5
Respiratory	N*	N	N	N	N	N	N	N	N	N	N
Motor activities	N*	N	N	N	N	N	N	N	N	N	N
Ocular signs	N*	N	N	N	N	N	N	N	N	N	N
Cardiovascular signs	N*	N	N	N	N	N	N	N	N	N	N
Analgesia	N*	N	N	N	N	N	N	N	N	N	N

021 91 30 9890 0992 60 62 450
Nikopharmed@gmail.com Nikopharmed.com

Gastrointestinal (Diarrhea, etc.)	N*	N	N	N	N	N	N	N	N	N	N
Convulsion	N*	N	N	N	N	N	N	N	N	N	N
Reflexes	N*	N	N	N	N	N	N	N	N	N	N
Salivation	N*	N	N	N	N	N	N	N	N	N	N
Piloerection	N*	N	N	N	N	N	N	N	N	N	N
Muscle tone	N*	N	N	N	N	N	N	N	N	N	N
Skin	N*	N	N	N	N	N	N	N	N	N	N
Death	-	-	-	-	-	-	-	-	-	-	-
Female		**6**	**7**	**8**	**9**	**10**	**6**	**7**	**8**	**9**	**10**
Respiratory	N*	N	N	N	N	N	N	N	N	N	N
Motor activities	N*	N	N	N	N	N	N	N	N	N	N
Ocular signs	N*	N	N	N	N	N	N	N	N	N	N
Cardiovascular signs	N*	N	N	N	N	N	N	N	N	N	N
Analgesia	N*	N	N	N	N	N	N	N	N	N	N
Gastrointestinal (Diarrhea, etc.)	N*	N	N	N	N	N	N	N	N	N	N
Convulsion	N*	N	N	N	N	N	N	N	N	N	N
Reflexes	N*	N	N	N	N	N	N	N	N	N	N
Salivation	N*	N	N	N	N	N	N	N	N	N	N
Piloerection	N*	N	N	N	N	N	N	N	N	N	N
Muscle tone	N*	N	N	N	N	N	N	N	N	N	N
Skin	N*	N	N	N	N	N	N	N	N	N	N
Death	-	-	-	-	-	-	-	-	-	-	-
N: No signs of Clinical Observations, **N.M**: Not Measured											
21th Day											
B) Clinical Observations											
Male		**1**	**2**	**3**	**4**	**5**	**1**	**2**	**3**	**4**	**5**
Respiratory	N*	N	N	N	N	N	N	N	N	N	N
Motor activities	N*	N	N	N	N	N	N	N	N	N	N
Ocular signs	N*	N	N	N	N	N	N	N	N	N	N
Cardiovascular signs	N*	N	N	N	N	N	N	N	N	N	N
Analgesia	N*	N	N	N	N	N	N	N	N	N	N
Gastrointestinal (Diarrhea, etc.)	N*	N	N	N	N	N	N	N	N	N	N
Convulsion	N*	N	N	N	N	N	N	N	N	N	N
Reflexes	N*	N	N	N	N	N	N	N	N	N	N
Salivation	N*	N	N	N	N	N	N	N	N	N	N
Piloerection	N*	N	N	N	N	N	N	N	N	N	N
Muscle tone	N*	N	N	N	N	N	N	N	N	N	N
Skin	N*	N	N	N	N	N	N	N	N	N	N
Death	-	-	-	-	-	-	-	-	-	-	-
Female		**6**	**7**	**8**	**9**	**10**	**6**	**7**	**8**	**9**	**10**
Respiratory	N*	N	N	N	N	N	N	N	N	N	N

021 91 30 9890 0992 60 62 450
Nikopharmed@gmail.com Nikopharmed.com

Motor activities	N*	N	N	N	N	N	N	N	N	N	N
Ocular signs	N*	N	N	N	N	N	N	N	N	N	N
Cardiovascular signs	N*	N	N	N	N	N	N	N	N	N	N
Analgesia	N*	N	N	N	N	N	N	N	N	N	N
Gastrointestinal (Diarrhea, etc.)	N*	N	N	N	N	N	N	N	N	N	N
Convulsion	N*	N	N	N	N	N	N	N	N	N	N
Reflexes	N*	N	N	N	N	N	N	N	N	N	N
Salivation	N*	N	N	N	N	N	N	N	N	N	N
Piloerection	N*	N	N	N	N	N	N	N	N	N	N
Muscle tone	N*	N	N	N	N	N	N	N	N	N	N
Skin	N*	N	N	N	N	N	N	N	N	N	N
Death	-	-	-	-	-	-	-	-	-	-	-
N: No signs of Clinical Observations, **N.M**: Not Measured											
28th Day											
B) Clinical Observations											
Male		**1**	**2**	**3**	**4**	**5**	**1**	**2**	**3**	**4**	**5**
Respiratory	N*	N	N	N	N	N	N	N	N	N	N
Motor activities	N*	N	N	N	N	N	N	N	N	N	N
Ocular signs	N*	N	N	N	N	N	N	N	N	N	N
Cardiovascular signs	N*	N	N	N	N	N	N	N	N	N	N
Analgesia	N*	N	N	N	N	N	N	N	N	N	N
Gastrointestinal (Diarrhea, etc.)	N*	N	N	N	N	N	N	N	N	N	N
Convulsion	N*	N	N	N	N	N	N	N	N	N	N
Reflexes	N*	N	N	N	N	N	N	N	N	N	N
Salivation	N*	N	N	N	N	N	N	N	N	N	N
Piloerection	N*	N	N	N	N	N	N	N	N	N	N
Muscle tone	N*	N	N	N	N	N	N	N	N	N	N
Skin	N*	N	N	N	N	N	N	N	N	N	N
Death	-	-	-	-	-	-	-	-	-	-	-
Female		**6**	**7**	**8**	**9**	**10**	**6**	**7**	**8**	**9**	**10**
Respiratory	N*	N	N	N	N	N	N	N	N	N	N
Motor activities	N*	N	N	N	N	N	N	N	N	N	N
Ocular signs	N*	N	N	N	N	N	N	N	N	N	N
Cardiovascular signs	N*	N	N	N	N	N	N	N	N	N	N
Analgesia	N*	N	N	N	N	N	N	N	N	N	N
Gastrointestinal (Diarrhea, etc.)	N*	N	N	N	N	N	N	N	N	N	N
Convulsion	N*	N	N	N	N	N	N	N	N	N	N
Reflexes	N*	N	N	N	N	N	N	N	N	N	N
Salivation	N*	N	N	N	N	N	N	N	N	N	N
Piloerection	N*	N	N	N	N	N	N	N	N	N	N
Muscle tone	N*	N	N	N	N	N	N	N	N	N	N

021 91 30 9890 0992 60 62 450
Nikopharmed@gmail.com Nikopharmed.com

Skin	N*	N	N	N	N	N	N	N	N	N	N
Death	-	-	-	-	-	-	-	-	-	-	-
N: No signs of Clinical Observations, **N.M**: Not Measured											
C) Organ Weight		Treatment					Control				
Animals No.		**1**	**2**	**3**	**4**	**5**	**1**	**2**	**3**	**4**	**5**
Liver	Male	1.28	1.32	1.51	1.46	1.41	1.63	1.74	1.67	1.54	1.6
Kidneys		0.48	0.52	0.62	0.56	0.67	0.51	0.52	0.49	0.54	0.52
Heart		0.33	0.31	0.28	0.33	0.32	0.24	0.25	0.25	0.33	0.36
Lungs		0.24	0.31	0.35	0.29	0.34	0.24	0.31	0.36	0.32	0.27
Animals No.		**6**	**7**	**8**	**9**	**10**	**6**	**7**	**8**	**9**	**10**
Liver	Female	1.36	1.42	1.48	1.54	1.57	1.68	1.47	1.63	1.59	1.68
Kidneys		0.61	0.45	0.63	0.55	0.65	0.53	0.52	0.62	0.66	0.52
Heart		0.29	0.31	0.32	0.33	0.34	0.23	0.27	0.27	0.21	0.27
Lungs		0.3	0.29	0.28	0.25	0.26	0.27	0.27	0.26	0.32	0.29
D) Gross Pathology											
Animals No.		**1**	**2**	**3**	**4**	**5**	**1**	**2**	**3**	**4**	**5**
Abdominal Cavity	N* (Male)	N	N	N	N	N	N	N	N	N	N
Thoracic Cavity		N	N	N	N	N	N	N	N	N	N
External surface of the body		N	N	N	N	N	N	N	N	N	N
All natural holes in the body (such as eyes, mouth, nose, anus)		N	N	N	N	N	N	N	N	N	N
Animals No.		**6**	**7**	**8**	**9**	**10**	**6**	**7**	**8**	**9**	**10**
Abdominal Cavity	N* (Female)	N	N	N	N	N	N	N	N	N	N
Thoracic Cavity		N	N	N	N	N	N	N	N	N	N
External surface of the body		N	N	N	N	N	N	N	N	N	N
All natural holes in the body (such as eyes, mouth, nose, anus)		N	N	N	N	N	N	N	N	N	N
N: No signs of Clinical Observations, **N.M**: Not Measured											

E) Organ Weight: Since ISO 10993-11 applies the term "should" (recommendation) rather than "shall" (obligation), and considering the absence of mortality or clinical signs, together with the low systemic toxicological concern, the omission of histopathology, clinical biochemistry, and organ weight measurements in the acute, subacute, and sub chronic systemic toxicity studies is scientifically justified and remains compliant with ISO 10993-11:2017, provided that this rationale is documented in the protocol and final study report.

F) Histopathology: Since ISO 10993-11 applies the term "should" (recommendation) rather than "shall" (obligation), and considering the absence of mortality or clinical signs, together with the low systemic toxicological concern, the omission of histopathology, clinical biochemistry, and organ weight measurements in the acute, subacute, and sub chronic systemic toxicity studies is scientifically justified and remains compliant with ISO 10993-11:2017, provided that this rationale is documented in the protocol and final study report.

G) Clinical Pathology (Hematology and clinical chemistry):
Since ISO 10993-11 applies the term "should" (recommendation) rather than "shall" (obligation), and considering the absence of mortality or clinical signs, together with the low systemic toxicological concern, the omission of histopathology, clinical biochemistry, and organ weight measurements in the acute, subacute, and sub chronic

021 91 30 9890 0992 60 62 450
Nikopharmed@gmail.com Nikopharmed.com

systemic toxicity studies is scientifically justified and remains compliant with ISO 10993-11:2017, provided that this rationale is documented in the protocol and final study report.

- **Scientific Justification for the Omission of Histopathology, Clinical Biochemistry, and Organ Weight Measurements:**

According to ISO 10993-11:2017 In ISO 10993-11:2017 (section on subacute and sub chronic systemic toxicity, and Annex D), the evaluations of histopathology, clinical biochemistry, and organ weight measurements are described using the wording "should be", indicating strong recommendations rather than mandatory requirements. Annex D is informative, listing suggested endpoints rather than prescriptive obligations. Therefore, omission of these parameters is acceptable when supported by a documented scientific rationale. In the present study, omission of these endpoints is scientifically justified based on the following considerations:

Non-Polar Extract											
Description	**Acceptable limit**	**Animals No. & Groups**									
		Treatments					**Controls**				
C) Body Weight Changes											
Male		**1**	**2**	**3**	**4**	**5**	**1**	**2**	**3**	**4**	**5**
Beginning of Test (g)	**25-30 (g)**	29.1	26.9	29.2	25.5	27.1	25.8	26.1	27	25.2	25
Day 7 (g)		29.9	27.2	30.3	26.6	28.6	27.7	28	29.5	27.3	28.4
Day 14 (g)		30.3	28.4	29.9	27.9	29.5	29	27.4	30.1	30	29
Day 21 (g)		31.3	29.5	30.4	28.3	30.4	31.7	31.4	32.4	31.5	32.3
End of Test (Day 28 (g))		31.7	30.7	31.2	29.1	31.7	32.9	34.2	34.8	33.1	35
Mean	**±20%**	29.23					29.79				
± SD		1.64					2.96				
Female		**6**	**7**	**8**	**9**	**10**	**6**	**7**	**8**	**9**	**10**
Beginning of Test (g)	**25-30 (g)**	25.2	26.8	27.2	29.3	27.9	25.9	27.1	26.6	30	29.6
Day 7 (g)		26.2	27.4	28.1	28.5	28.1	28	29.4	29	32.3	30.2
Day 14 (g)		27.5	28.7	29.5	29.6	29.9	27.5	30.2	28.4	31.5	32.1
Day 21 (g)		28.3	29.6	30.6	30.7	30.6	28.3	33	29.7	34.6	34
End of Test (Day 28 (g))		29.4	31.1	31.3	31.4	31.7	29.9	32.7	32	33.2	33.7
Mean	**±20%**	28.98					30.36				
± SD		1.69					2.40				
7th Day											
D) Clinical Observations											
Male		**1**	**2**	**3**	**4**	**5**	**1**	**2**	**3**	**4**	**5**
Respiratory	N*	N	N	N	N	N	N	N	N	N	N
Motor activities	N*	N	N	N	N	N	N	N	N	N	N
Ocular signs	N*	N	N	N	N	N	N	N	N	N	N
Cardiovascular signs	N*	N	N	N	N	N	N	N	N	N	N
Analgesia	N*	N	N	N	N	N	N	N	N	N	N
Gastrointestinal (Diarrhea, etc.)	N*	N	N	N	N	N	N	N	N	N	N

021 91 30 9890 0992 60 62 450
Nikopharmed@gmail.com Nikopharmed.com

Convulsion	N*	N	N	N	N	N	N	N	N	N	N
Reflexes	N*	N	N	N	N	N	N	N	N	N	N
Salivation	N*	N	N	N	N	N	N	N	N	N	N
Piloerection	N*	N	N	N	N	N	N	N	N	N	N
Muscle tone	N*	N	N	N	N	N	N	N	N	N	N
Skin	N*	N	N	N	N	N	N	N	N	N	N
Death	-	-	-	-	-	-	-	-	-	-	-
Female		**6**	**7**	**8**	**9**	**10**	**6**	**7**	**8**	**9**	**10**
Respiratory	N*	N	N	N	N	N	N	N	N	N	N
Motor activities	N*	N	N	N	N	N	N	N	N	N	N
Ocular signs	N*	N	N	N	N	N	N	N	N	N	N
Cardiovascular signs	N*	N	N	N	N	N	N	N	N	N	N
Analgesia	N*	N	N	N	N	N	N	N	N	N	N
Gastrointestinal (Diarrhea, etc.)	N*	N	N	N	N	N	N	N	N	N	N
Convulsion	N*	N	N	N	N	N	N	N	N	N	N
Reflexes	N*	N	N	N	N	N	N	N	N	N	N
Salivation	N*	N	N	N	N	N	N	N	N	N	N
Piloerection	N*	N	N	N	N	N	N	N	N	N	N
Muscle tone	N*	N	N	N	N	N	N	N	N	N	N
Skin	N*	N	N	N	N	N	N	N	N	N	N
Death	-	-	-	-	-	-	-	-	-	-	-

N: No signs of Clinical Observations, **N.M**: Not Measured

14th Day

B) Clinical Observations

Male		**1**	**2**	**3**	**4**	**5**	**1**	**2**	**3**	**4**	**5**
Respiratory	N*	N	N	N	N	N	N	N	N	N	N
Motor activities	N*	N	N	N	N	N	N	N	N	N	N
Ocular signs	N*	N	N	N	N	N	N	N	N	N	N
Cardiovascular signs	N*	N	N	N	N	N	N	N	N	N	N
Analgesia	N*	N	N	N	N	N	N	N	N	N	N
Gastrointestinal (Diarrhea, etc.)	N*	N	N	N	N	N	N	N	N	N	N
Convulsion	N*	N	N	N	N	N	N	N	N	N	N
Reflexes	N*	N	N	N	N	N	N	N	N	N	N
Salivation	N*	N	N	N	N	N	N	N	N	N	N
Piloerection	N*	N	N	N	N	N	N	N	N	N	N
Muscle tone	N*	N	N	N	N	N	N	N	N	N	N
Skin	N*	N	N	N	N	N	N	N	N	N	N
Death	-	-	-	-	-	-	-	-	-	-	-
Female		**6**	**7**	**8**	**9**	**10**	**6**	**7**	**8**	**9**	**10**
Respiratory	N*	N	N	N	N	N	N	N	N	N	N
Motor activities	N*	N	N	N	N	N	N	N	N	N	N

021 91 30 9890 0992 60 62 450
Nikopharmed@gmail.com Nikopharmed.com

Ocular signs	N*	N	N	N	N	N	N	N	N	N	N
Cardiovascular signs	N*	N	N	N	N	N	N	N	N	N	N
Analgesia	N*	N	N	N	N	N	N	N	N	N	N
Gastrointestinal (Diarrhea, etc.)	N*	N	N	N	N	N	N	N	N	N	N
Convulsion	N*	N	N	N	N	N	N	N	N	N	N
Reflexes	N*	N	N	N	N	N	N	N	N	N	N
Salivation	N*	N	N	N	N	N	N	N	N	N	N
Piloerection	N*	N	N	N	N	N	N	N	N	N	N
Muscle tone	N*	N	N	N	N	N	N	N	N	N	N
Skin	N*	N	N	N	N	N	N	N	N	N	N
Death	-	-	-	-	-	-	-	-	-	-	-
N: No signs of Clinical Observations, **N.M**: Not Measured											
21th Day											
B) Clinical Observations											
Male		**1**	**2**	**3**	**4**	**5**	**1**	**2**	**3**	**4**	**5**
Respiratory	N*	N	N	N	N	N	N	N	N	N	N
Motor activities	N*	N	N	N	N	N	N	N	N	N	N
Ocular signs	N*	N	N	N	N	N	N	N	N	N	N
Cardiovascular signs	N*	N	N	N	N	N	N	N	N	N	N
Analgesia	N*	N	N	N	N	N	N	N	N	N	N
Gastrointestinal (Diarrhea, etc.)	N*	N	N	N	N	N	N	N	N	N	N
Convulsion	N*	N	N	N	N	N	N	N	N	N	N
Reflexes	N*	N	N	N	N	N	N	N	N	N	N
Salivation	N*	N	N	N	N	N	N	N	N	N	N
Piloerection	N*	N	N	N	N	N	N	N	N	N	N
Muscle tone	N*	N	N	N	N	N	N	N	N	N	N
Skin	N*	N	N	N	N	N	N	N	N	N	N
Death	-	-	-	-	-	-	-	-	-	-	-
Female		**6**	**7**	**8**	**9**	**10**	**6**	**7**	**8**	**9**	**10**
Respiratory	N*	N	N	N	N	N	N	N	N	N	N
Motor activities	N*	N	N	N	N	N	N	N	N	N	N
Ocular signs	N*	N	N	N	N	N	N	N	N	N	N
Cardiovascular signs	N*	N	N	N	N	N	N	N	N	N	N
Analgesia	N*	N	N	N	N	N	N	N	N	N	N
Gastrointestinal (Diarrhea, etc.)	N*	N	N	N	N	N	N	N	N	N	N
Convulsion	N*	N	N	N	N	N	N	N	N	N	N
Reflexes	N*	N	N	N	N	N	N	N	N	N	N
Salivation	N*	N	N	N	N	N	N	N	N	N	N
Piloerection	N*	N	N	N	N	N	N	N	N	N	N
Muscle tone	N*	N	N	N	N	N	N	N	N	N	N
Skin	N*	N	N	N	N	N	N	N	N	N	N

021 91 30 9890 0992 60 62 450
Nikopharmed@gmail.com Nikopharmed.com

Death	-	-	-	-	-	-	-	-	-	-	-
N: No signs of Clinical Observations, **N.M**: Not Measured											
28th Day											
B) Clinical Observations											
Male		**1**	**2**	**3**	**4**	**5**	**1**	**2**	**3**	**4**	**5**
Respiratory	N*	N	N	N	N	N	N	N	N	N	N
Motor activities	N*	N	N	N	N	N	N	N	N	N	N
Ocular signs	N*	N	N	N	N	N	N	N	N	N	N
Cardiovascular signs	N*	N	N	N	N	N	N	N	N	N	N
Analgesia	N*	N	N	N	N	N	N	N	N	N	N
Gastrointestinal (Diarrhea, etc.)	N*	N	N	N	N	N	N	N	N	N	N
Convulsion	N*	N	N	N	N	N	N	N	N	N	N
Reflexes	N*	N	N	N	N	N	N	N	N	N	N
Salivation	N*	N	N	N	N	N	N	N	N	N	N
Piloerection	N*	N	N	N	N	N	N	N	N	N	N
Muscle tone	N*	N	N	N	N	N	N	N	N	N	N
Skin	N*	N	N	N	N	N	N	N	N	N	N
Death	-	-	-	-	-	-	-	-	-	-	-
Female		**6**	**7**	**8**	**9**	**10**	**6**	**7**	**8**	**9**	**10**
Respiratory	N*	N	N	N	N	N	N	N	N	N	N
Motor activities	N*	N	N	N	N	N	N	N	N	N	N
Ocular signs	N*	N	N	N	N	N	N	N	N	N	N
Cardiovascular signs	N*	N	N	N	N	N	N	N	N	N	N
Analgesia	N*	N	N	N	N	N	N	N	N	N	N
Gastrointestinal (Diarrhea, etc.)	N*	N	N	N	N	N	N	N	N	N	N
Convulsion	N*	N	N	N	N	N	N	N	N	N	N
Reflexes	N*	N	N	N	N	N	N	N	N	N	N
Salivation	N*	N	N	N	N	N	N	N	N	N	N
Piloerection	N*	N	N	N	N	N	N	N	N	N	N
Muscle tone	N*	N	N	N	N	N	N	N	N	N	N
Skin	N*	N	N	N	N	N	N	N	N	N	N
Death	-	-	-	-	-	-	-	-	-	-	-
N: No signs of Clinical Observations, **N.M**: Not Measured											
C) Organ Weight		Treatment					Control				
Animals No.		**1**	**2**	**3**	**4**	**5**	**1**	**2**	**3**	**4**	**5**
Liver	Male	1. 77	1.87	2.09	2.07	1.83	2.15	1.83	2.02	2.17	2.07
Kidneys		1.23	1.16	1.43	1.26	1.74	1.83	1.75	1.81	1.70	1.01
Heart		1.06	1.15	0.55	0.91	0.47	0.81	0.73	1.06	0.97	1.13
Lungs		1.14	1.18	1.21	1.16	1.14	1.1	1.12	1.13	1.17	1.19
Animals No.		**6**	**7**	**8**	**9**	**10**	**6**	**7**	**8**	**9**	**10**
Liver	Female	1.87	2.01	1.87	2.12	2.11	1.93	2.06	2.03	1.42	1.36

021 91 30 9890 0992 60 62 450
Nikopharmed@gmail.com Nikopharmed.com

Kidneys		0.66	0.58	0.59	1.02	0.44	0.74	0.69	0.62	0.29	0.86
Heart		1.05	0.97	0.96	0.89	1.09	0.84	0.89	0.9	0.97	0.78
Lungs		1.22	1.18	1.19	1.21	1.17	1.12	1.15	1.13	1.27	1.13
D) Gross Pathology											
Animals No.		**1**	**2**	**3**	**4**	**5**	**1**	**2**	**3**	**4**	**5**
Abdominal Cavity	**N*** (Male)	N	N	N	N	N	N	N	N	N	N
Thoracic Cavity		N	N	N	N	N	N	N	N	N	N
External surface of the body		N	N	N	N	N	N	N	N	N	N
All natural holes in the body (such as eyes, mouth, nose, anus)		N	N	N	N	N	N	N	N	N	N
Animals No.		**6**	**7**	**8**	**9**	**10**	**6**	**7**	**8**	**9**	**10**
Abdominal Cavity	**N*** (Female)	N	N	N	N	N	N	N	N	N	N
Thoracic Cavity		N	N	N	N	N	N	N	N	N	N
External surface of the body		N	N	N	N	N	N	N	N	N	N
All natural holes in the body (such as eyes, mouth, nose, anus)		N	N	N	N	N	N	N	N	N	N
N: No signs of Clinical Observations, **N.M**: Not Measured											

E) Organ Weight: Since ISO 10993-11 applies the term "should" (recommendation) rather than "shall" (obligation), and considering the absence of mortality or clinical signs, together with the low systemic toxicological concern, the omission of histopathology, clinical biochemistry, and organ weight measurements in the acute, subacute, and sub chronic systemic toxicity studies is scientifically justified and remains compliant with ISO 10993-11:2017, provided that this rationale is documented in the protocol and final study report.

F) Histopathology: Since ISO 10993-11 applies the term "should" (recommendation) rather than "shall" (obligation), and considering the absence of mortality or clinical signs, together with the low systemic toxicological concern, the omission of histopathology, clinical biochemistry, and organ weight measurements in the acute, subacute, and sub chronic systemic toxicity studies is scientifically justified and remains compliant with ISO 10993-11:2017, provided that this rationale is documented in the protocol and final study report.

G) Clinical Pathology (Hematology and clinical chemistry):
Since ISO 10993-11 applies the term "should" (recommendation) rather than "shall" (obligation), and considering the absence of mortality or clinical signs, together with the low systemic toxicological concern, the omission of histopathology, clinical biochemistry, and organ weight measurements in the acute, subacute, and sub chronic systemic toxicity studies is scientifically justified and remains compliant with ISO 10993-11:2017, provided that this rationale is documented in the protocol and final study report.

- **Scientific Justification for the Omission of Histopathology, Clinical Biochemistry, and Organ Weight Measurements:**

According to ISO 10993-11:2017 In ISO 10993-11:2017 (section on subacute and sub chronic systemic toxicity, and Annex D), the evaluations of histopathology, clinical biochemistry, and organ weight measurements are described using the wording "should be", indicating strong recommendations rather than mandatory requirements. Annex D is informative, listing suggested endpoints rather than prescriptive obligations. Therefore, omission of these parameters is acceptable when supported by a documented scientific rationale. In the present study, omission of these endpoints is scientifically justified based on the following considerations:

021 91 30 9890 0992 60 62 450
Nikopharmed@gmail.com Nikopharmed.com

PHOTOGRAPH OF THE TEST ARTICLE

Macroscopic Examination

Gross Pathology (Polar)	
Male	
Control	**Sample**
	
Normal	**Normal**
Female	
Control	**Sample**
	
Normal	**Normal**

021 91 30 9890 0992 60 62 450
Nikopharmed@gmail.com Nikopharmed.com

Conclusion

- None of the tested animals exhibited abnormal **Clinical Signs** in terms of toxicity during the test period.
- All the animals were **Alive** during the test duration.
- The **Body Weight** changes were within the acceptable range during the test.
- None of the animals exhibited abnormal **Gross Pathology** indicative of toxicity during the test period.
- The **Organ Weight** changes were within the acceptable range during the test

The results provide evidence to support that the examined product is **Non-sub acute Toxicity.**

References

1. ISO 10993-11:2017, Biological evaluation of medical devices, Part 11: Tests for systemic toxicity
2. ISO 10993-12:2021, Biological evaluation of medical devices, Part 12: Sample preparation and reference materials.
3. ISO 10993-2: 2022, Biological evaluation of medical devices, Part 2: Animal welfare requirements.

Description Based on the customer request according to the F02-p12/05

Test Performer: *Z. Sayyahi*	**Lab. Manager:** *M. Daliri*	**CEO:** *M.Borjian*	**Nikopharmed laboratory sign**
Sign:	Sign:	Sign:	



- *Test results are only related to the tested products.*
- *Reproduction of test results without the permission of the laboratory is prohibited.*
- *Sampling has been done by the customer.*
- *This report is not valid without the seal and signature of the CEO.*
- *If the tests were performed by the contractor, the name of the contractor is given in the description section.*
- *Any objection to the issued results can be processed within 7 days after the date of issuance of the result.*
- *If the sample is stable, after the test, the sample will be stored in the laboratory for one month.*
- *Expanded uncertainty (CI: 95% , K=2) is calculated for quantitative tests and included upon customer request.*
- *Nikopharmed Arya Company, National Institute of Genetic Engineering and Biotechnology, Pajuhesh Boulevard, 17km Tehran-Karaj Highway, Tehran, Iran*

021 91 30 9890 0992 60 62 450
Nikopharmed@gmail.com Nikopharmed.com